RU2744974C2 - Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk - Google Patents
Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk Download PDFInfo
- Publication number
- RU2744974C2 RU2744974C2 RU2018110379A RU2018110379A RU2744974C2 RU 2744974 C2 RU2744974 C2 RU 2744974C2 RU 2018110379 A RU2018110379 A RU 2018110379A RU 2018110379 A RU2018110379 A RU 2018110379A RU 2744974 C2 RU2744974 C2 RU 2744974C2
- Authority
- RU
- Russia
- Prior art keywords
- mmol
- mixture
- tert
- stirred
- etoac
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 203
- 238000011282 treatment Methods 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 title description 277
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract description 8
- 230000001594 aberrant effect Effects 0.000 claims abstract description 7
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 230000000508 neurotrophic effect Effects 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 359
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 181
- -1 Cone-C6 alkyl Chemical group 0.000 description 169
- 235000019439 ethyl acetate Nutrition 0.000 description 169
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- 238000006243 chemical reaction Methods 0.000 description 117
- 239000000243 solution Substances 0.000 description 117
- 239000004698 Polyethylene Substances 0.000 description 98
- 238000005160 1H NMR spectroscopy Methods 0.000 description 75
- 238000004809 thin layer chromatography Methods 0.000 description 73
- 125000000753 cycloalkyl group Chemical group 0.000 description 69
- 239000011734 sodium Substances 0.000 description 69
- 239000007787 solid Substances 0.000 description 67
- 239000007788 liquid Substances 0.000 description 66
- 230000015572 biosynthetic process Effects 0.000 description 59
- 238000003786 synthesis reaction Methods 0.000 description 59
- 125000000623 heterocyclic group Chemical group 0.000 description 57
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 57
- 239000011541 reaction mixture Substances 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 54
- 239000012044 organic layer Substances 0.000 description 52
- 125000003118 aryl group Chemical group 0.000 description 49
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 239000002244 precipitate Substances 0.000 description 40
- 125000004404 heteroalkyl group Chemical group 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 37
- 239000002904 solvent Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000007858 starting material Substances 0.000 description 35
- 125000000217 alkyl group Chemical group 0.000 description 33
- 125000003545 alkoxy group Chemical group 0.000 description 32
- 229910052736 halogen Inorganic materials 0.000 description 32
- 150000002367 halogens Chemical class 0.000 description 32
- 239000012043 crude product Substances 0.000 description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 31
- 229920006395 saturated elastomer Polymers 0.000 description 31
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 238000010898 silica gel chromatography Methods 0.000 description 29
- 125000001188 haloalkyl group Chemical group 0.000 description 28
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 27
- BKRHQMHIXPQFQI-UHFFFAOYSA-N 4-oxo-1,2-dihydropyrazolo[3,4-d]pyrimidine-3-carboxylic acid Chemical compound C1=NC(=O)C2=C(C(=O)O)NNC2=N1 BKRHQMHIXPQFQI-UHFFFAOYSA-N 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 239000012267 brine Substances 0.000 description 24
- 125000004093 cyano group Chemical group *C#N 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 125000002947 alkylene group Chemical group 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- 238000000746 purification Methods 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 125000004429 atom Chemical group 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 125000004438 haloalkoxy group Chemical group 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000012298 atmosphere Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 13
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- JCGDTBHMOCDGSY-LLUDDFSJSA-N (1r,2r,5r)-2-[[(1s)-1-phenylethyl]amino]-5-phenylmethoxycyclohexan-1-ol Chemical compound O([C@@H]1CC[C@H]([C@@H](C1)O)N[C@@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 JCGDTBHMOCDGSY-LLUDDFSJSA-N 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 238000012746 preparative thin layer chromatography Methods 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FXOFSGSXPYHEMV-XVMARJQXSA-N (3as,4s,6ar)-2,2-dimethyl-4,6a-dihydro-3ah-cyclopenta[d][1,3]dioxol-4-ol Chemical compound C1=C[C@H](O)[C@@H]2OC(C)(C)O[C@@H]21 FXOFSGSXPYHEMV-XVMARJQXSA-N 0.000 description 6
- DTBKKESEAXYGMM-UHFFFAOYSA-N 3-bromo-2h-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C(Br)=NNC2=C1 DTBKKESEAXYGMM-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000004296 chiral HPLC Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000002798 polar solvent Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- QZQVDIVTVLELOB-HSUXUTPPSA-N (1R,3R,4R)-4-aminocyclohexane-1,3-diol Chemical compound N[C@@H]1CC[C@@H](O)C[C@H]1O QZQVDIVTVLELOB-HSUXUTPPSA-N 0.000 description 5
- OHUKQADMTXLANM-XJXBIZEQSA-N (1r,2r,4r)-2-[tert-butyl(dimethyl)silyl]oxy-n-[(1s)-1-phenylethyl]-4-phenylmethoxycyclohexan-1-amine Chemical compound O([C@@H]1CC[C@H]([C@@H](C1)O[Si](C)(C)C(C)(C)C)N[C@@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 OHUKQADMTXLANM-XJXBIZEQSA-N 0.000 description 5
- ALWOGRCGRHKOFW-UHFFFAOYSA-N 2-[(3-bromo-4-chloropyrazolo[3,4-d]pyrimidin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)N=C(Br)C2=C1Cl ALWOGRCGRHKOFW-UHFFFAOYSA-N 0.000 description 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 5
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001414 amino alcohols Chemical class 0.000 description 5
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- BFHDJRWZCINSEQ-HSUXUTPPSA-N (1R,2R,4R)-2-amino-4-methylsulfonylcyclopentan-1-ol Chemical compound N[C@H]1[C@@H](C[C@@H](C1)S(=O)(=O)C)O BFHDJRWZCINSEQ-HSUXUTPPSA-N 0.000 description 4
- ZKCGXZHSOARULJ-FRRDWIJNSA-N (1s,4r,6r)-4-phenylmethoxy-7-oxabicyclo[4.1.0]heptane Chemical compound O([C@H]1C[C@H]2O[C@H]2CC1)CC1=CC=CC=C1 ZKCGXZHSOARULJ-FRRDWIJNSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- LJFDHNGCSYMHDC-WMLDXEAASA-N ClC1=C2C(=NC=N1)N(N=C2C(=O)N1[C@H](C[C@@H](C1)F)C1=C(C=CC(=C1)F)F)COCC[Si](C)(C)C Chemical compound ClC1=C2C(=NC=N1)N(N=C2C(=O)N1[C@H](C[C@@H](C1)F)C1=C(C=CC(=C1)F)F)COCC[Si](C)(C)C LJFDHNGCSYMHDC-WMLDXEAASA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- BMZCVVCVCDSALX-UHFFFAOYSA-N cyclohex-3-en-1-yloxymethylbenzene Chemical compound C=1C=CC=CC=1COC1CCC=CC1 BMZCVVCVCDSALX-UHFFFAOYSA-N 0.000 description 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- VFNBELKXKOPBJT-HSUXUTPPSA-N methyl (1R,3R,4R)-3-amino-4-hydroxycyclopentane-1-carboxylate Chemical compound N[C@@H]1C[C@H](C[C@H]1O)C(=O)OC VFNBELKXKOPBJT-HSUXUTPPSA-N 0.000 description 4
- SSATZBUCOTXXGA-IWSPIJDZSA-N methyl (1r,3r,4r)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylate Chemical compound COC(=O)[C@H]1C[C@@H](O)[C@H](NC(=O)OC(C)(C)C)C1 SSATZBUCOTXXGA-IWSPIJDZSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 229910052705 radium Inorganic materials 0.000 description 4
- 229910052701 rubidium Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- ASPAKSDHNNXVIB-LLVKDONJSA-N tert-butyl (4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)CC1=O ASPAKSDHNNXVIB-LLVKDONJSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- FRWUUYAEAFLDLQ-MRVPVSSYSA-N (1R)-1-(2-chloro-5-fluoropyridin-3-yl)but-3-en-1-amine Chemical compound ClC1=NC=C(C=C1[C@@H](CC=C)N)F FRWUUYAEAFLDLQ-MRVPVSSYSA-N 0.000 description 3
- LLDIFHPLOFXLEQ-JHJVBQTASA-N (1R,2R,4R)-2-[[3-bromo-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidin-4-yl]amino]-4-methylsulfonylcyclopentan-1-ol Chemical compound BrC1=NN(C2=NC=NC(=C21)N[C@H]1[C@@H](C[C@@H](C1)S(=O)(=O)C)O)COCC[Si](C)(C)C LLDIFHPLOFXLEQ-JHJVBQTASA-N 0.000 description 3
- DGGCJLFUXOIOQH-WCMLQCRESA-N (1R,2R,4S,5R,6S)-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonan-5-amine Chemical compound CC1(O[C@H]2[C@@H](O1)[C@@H]([C@@H]1[C@H]2C1)N)C DGGCJLFUXOIOQH-WCMLQCRESA-N 0.000 description 3
- IIRDPYYCADCHRS-HSUXUTPPSA-N (1R,3R,4R)-3-amino-4-hydroxycyclopentane-1-carbonitrile Chemical compound N[C@@H]1C[C@H](C[C@H]1O)C#N IIRDPYYCADCHRS-HSUXUTPPSA-N 0.000 description 3
- LUFYOKRQPSBJIS-BWZBUEFSSA-N (1R,3R,4R)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1C[C@H](C[C@H]1O)C(=O)O LUFYOKRQPSBJIS-BWZBUEFSSA-N 0.000 description 3
- GJFYOSYIUWJBTD-DEVUXVJFSA-N (1S,2R,5R)-2-amino-5-fluorocyclopentan-1-ol hydrochloride Chemical compound Cl.N[C@@H]1CC[C@@H](F)[C@H]1O GJFYOSYIUWJBTD-DEVUXVJFSA-N 0.000 description 3
- ZYVIUFSUCZLDTO-DMDPSCGWSA-N (1S,2R,5S)-2-[[3-bromo-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidin-4-yl]amino]-5-fluorocyclopentan-1-ol Chemical compound BrC1=NN(C2=NC=NC(=C21)N[C@H]1[C@@H]([C@H](CC1)F)O)COCC[Si](C)(C)C ZYVIUFSUCZLDTO-DMDPSCGWSA-N 0.000 description 3
- QRTAWJHVRQCBIP-VPENINKCSA-N (1S,2R,5S)-2-amino-5-fluorocyclopentan-1-ol Chemical compound N[C@H]1[C@@H]([C@H](CC1)F)O QRTAWJHVRQCBIP-VPENINKCSA-N 0.000 description 3
- WRTDISXTWWFXTH-WOPDTQHZSA-N (1S,2R,5S)-2-azido-5-phenylmethoxycyclopentan-1-ol Chemical compound N(=[N+]=[N-])[C@H]1[C@@H]([C@H](CC1)OCC1=CC=CC=C1)O WRTDISXTWWFXTH-WOPDTQHZSA-N 0.000 description 3
- SPCYQHNDDCJHTC-YUPRTTJUSA-N (1S,2S,4S)-2-amino-4-fluorocyclopentan-1-ol Chemical compound N[C@@H]1[C@H](C[C@H](C1)F)O SPCYQHNDDCJHTC-YUPRTTJUSA-N 0.000 description 3
- HNLHTEPZSOZJND-SDDRHHMPSA-N (1S,2S,5S)-2-phenylmethoxy-6-oxabicyclo[3.1.0]hexane Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H]2O[C@H]2CC1 HNLHTEPZSOZJND-SDDRHHMPSA-N 0.000 description 3
- QWGIRDKDEKOYIB-MROZADKFSA-N (1S,5R,6R)-3,7-dioxabicyclo[4.1.0]heptan-5-ol Chemical compound O[C@@H]1COC[C@@H]2O[C@H]12 QWGIRDKDEKOYIB-MROZADKFSA-N 0.000 description 3
- PWQPGBOOZSURRK-CEXWTWQISA-N (1r,2r,5s)-n,n-dibenzyl-6-oxabicyclo[3.1.0]hexan-2-amine Chemical compound C=1C=CC=CC=1CN([C@H]1[C@H]2O[C@H]2CC1)CC1=CC=CC=C1 PWQPGBOOZSURRK-CEXWTWQISA-N 0.000 description 3
- PWQPGBOOZSURRK-QRVBRYPASA-N (1s,2r,5r)-n,n-dibenzyl-6-oxabicyclo[3.1.0]hexan-2-amine Chemical compound C=1C=CC=CC=1CN([C@H]1[C@@H]2O[C@@H]2CC1)CC1=CC=CC=C1 PWQPGBOOZSURRK-QRVBRYPASA-N 0.000 description 3
- PHMHDDCJMBXLMD-IPMKNSEASA-N (1s,2r,5s)-2-(dibenzylamino)-5-fluorocyclopentan-1-ol Chemical compound O[C@@H]1[C@@H](F)CC[C@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 PHMHDDCJMBXLMD-IPMKNSEASA-N 0.000 description 3
- KAZDROFVEVUJAW-WOPDTQHZSA-N (1s,2s,4r)-2-azido-4-phenylmethoxycyclopentan-1-ol Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](O)C[C@@H]1OCC1=CC=CC=C1 KAZDROFVEVUJAW-WOPDTQHZSA-N 0.000 description 3
- JCGDTBHMOCDGSY-FIRPJDEBSA-N (1s,2s,5s)-2-[[(1s)-1-phenylethyl]amino]-5-phenylmethoxycyclohexan-1-ol Chemical compound O([C@H]1CC[C@@H]([C@H](C1)O)N[C@@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 JCGDTBHMOCDGSY-FIRPJDEBSA-N 0.000 description 3
- WIDBVWOWNWWRFT-JHEVNIALSA-N (3R,4S,5R)-5-[[(1R)-1-phenylethyl]amino]oxane-3,4-diol Chemical compound C[C@@H](N[C@@H]1COC[C@@H](O)[C@H]1O)C1=CC=CC=C1 WIDBVWOWNWWRFT-JHEVNIALSA-N 0.000 description 3
- RYDQWPYEVUWVAX-WDCZJNDASA-N (3R,4S,5R)-5-aminooxane-3,4-diol Chemical compound N[C@H]1[C@@H]([C@@H](COC1)O)O RYDQWPYEVUWVAX-WDCZJNDASA-N 0.000 description 3
- IUSMVOVCNMKOSU-RDDDGLTNSA-N (3S,5R)-5-(2,5-difluorophenyl)pyrrolidine-3-carbonitrile Chemical compound FC1=C(C=C(C=C1)F)[C@H]1C[C@@H](CN1)C#N IUSMVOVCNMKOSU-RDDDGLTNSA-N 0.000 description 3
- BGNBJFIGIYMQPT-QYNIQEEDSA-N (3aS,4R,6aR)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-amine Chemical compound CC1(C)O[C@@H]2C=C[C@@H](N)[C@@H]2O1 BGNBJFIGIYMQPT-QYNIQEEDSA-N 0.000 description 3
- DGEOCKJLPWVDQU-SRQIZXRXSA-N (3aS,6R,6aS)-4,4-difluoro-2,2-dimethyl-3a,5,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-6-amine Chemical compound CC1(C)O[C@H]2[C@H](N)CC(F)(F)[C@H]2O1 DGEOCKJLPWVDQU-SRQIZXRXSA-N 0.000 description 3
- UWXUDHGKUWPPGB-RQJHMYQMSA-N (3ar,6ar)-2,2-dimethyl-3a,6a-dihydrocyclopenta[d][1,3]dioxol-4-one Chemical compound C1=CC(=O)[C@@H]2OC(C)(C)O[C@@H]21 UWXUDHGKUWPPGB-RQJHMYQMSA-N 0.000 description 3
- BEVGOGJIDJYUNN-MRVPVSSYSA-N (4r)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidin-2-one Chemical compound CC(C)(C)[Si](C)(C)O[C@H]1CNC(=O)C1 BEVGOGJIDJYUNN-MRVPVSSYSA-N 0.000 description 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- BKOQSTDQSSEHLD-NSPYISDASA-N (R)-N-[(1R)-1-(2-chloro-5-fluoropyridin-3-yl)but-3-enyl]-2-methylpropane-2-sulfinamide Chemical compound ClC1=NC=C(C=C1[C@@H](CC=C)N[S@](=O)C(C)(C)C)F BKOQSTDQSSEHLD-NSPYISDASA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- JHGLFGRVJLJVDT-UHFFFAOYSA-N 1-(2-bromo-5-chlorophenyl)-n-methylmethanamine Chemical compound CNCC1=CC(Cl)=CC=C1Br JHGLFGRVJLJVDT-UHFFFAOYSA-N 0.000 description 3
- UTKGZXVMMFBCJC-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C(CBr)=C1 UTKGZXVMMFBCJC-UHFFFAOYSA-N 0.000 description 3
- BRKRVFXSCZSHBR-MRTXSQPYSA-N 2-[(1R,2R,4S,5R,6S)-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonan-5-yl]isoindole-1,3-dione Chemical compound CC1(O[C@H]2[C@@H](O1)[C@@H]([C@@H]1[C@H]2C1)N1C(C2=CC=CC=C2C1=O)=O)C BRKRVFXSCZSHBR-MRTXSQPYSA-N 0.000 description 3
- JPVAQNKWJIQXOP-UPJWGTAASA-N 2-[(3aS,4R,6aR)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]isoindole-1,3-dione Chemical compound CC1(C)O[C@@H]2C=C[C@H]([C@@H]2O1)N1C(=O)C2=C(C=CC=C2)C1=O JPVAQNKWJIQXOP-UPJWGTAASA-N 0.000 description 3
- GCERGIDMVJEZFD-KGYLQXTDSA-N 2-[(3aS,6R,6aS)-2,2-dimethyl-4-oxo-3a,5,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-6-yl]isoindole-1,3-dione Chemical compound CC1(O[C@@H]2[C@H](O1)C(C[C@H]2N1C(C2=CC=CC=C2C1=O)=O)=O)C GCERGIDMVJEZFD-KGYLQXTDSA-N 0.000 description 3
- NNMWRODQSAEWHU-WOPDTQHZSA-N 2-[(3aS,6R,6aS)-4,4-difluoro-2,2-dimethyl-3a,5,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-6-yl]isoindole-1,3-dione Chemical compound CC1(C)O[C@H]2[C@@H](CC(F)(F)[C@H]2O1)N1C(=O)C2=C(C=CC=C2)C1=O NNMWRODQSAEWHU-WOPDTQHZSA-N 0.000 description 3
- MMYNCMNYRYZUTA-MROQNXINSA-N 2-[(3ar,4s,6r,6as)-4-hydroxy-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-6-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@@H]1C[C@H](O)[C@H]2OC(C)(C)O[C@H]21 MMYNCMNYRYZUTA-MROQNXINSA-N 0.000 description 3
- QRXVTUPWDPQZEG-UPJWGTAASA-N 2-[(3as,4r,6ar)-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@@H]1CC[C@H]2OC(C)(C)O[C@H]21 QRXVTUPWDPQZEG-UPJWGTAASA-N 0.000 description 3
- HUUMLJGKNHUSRP-POYBYMJQSA-N 2-chloro-5-fluoro-3-[(2R,4S)-4-fluoropyrrolidin-2-yl]pyridine Chemical compound ClC1=NC=C(C=C1[C@@H]1NC[C@H](C1)F)F HUUMLJGKNHUSRP-POYBYMJQSA-N 0.000 description 3
- UCBJPGXLZYKKNA-MRVPVSSYSA-N 3-[(2R)-4,4-difluoropyrrolidin-2-yl]-5-fluoropyridine Chemical compound FC1(C[C@@H](NC1)C=1C=NC=C(C=1)F)F UCBJPGXLZYKKNA-MRVPVSSYSA-N 0.000 description 3
- KCKAIFFKJSPMKW-DTWKUNHWSA-N 3-fluoro-5-[(2R,4S)-4-fluoropyrrolidin-2-yl]pyridine Chemical compound FC=1C=NC=C(C=1)[C@@H]1NC[C@H](C1)F KCKAIFFKJSPMKW-DTWKUNHWSA-N 0.000 description 3
- ALDYAAJAAVXYAW-TZMCWYRMSA-N 4-[[(1R,2R)-2-hydroxycyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carbaldehyde Chemical compound O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)N(N=C2C=O)COCC[Si](C)(C)C ALDYAAJAAVXYAW-TZMCWYRMSA-N 0.000 description 3
- WDQCTTUCSDHJCE-JHJVBQTASA-N 4-[[(1R,2R,4R)-2-hydroxy-4-methylsulfonylcyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxylic acid Chemical compound O[C@H]1[C@@H](C[C@H](C1)S(=O)(=O)C)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C WDQCTTUCSDHJCE-JHJVBQTASA-N 0.000 description 3
- CDVSPTPCZCIMOT-MISXGVKJSA-N 4-[[(1R,2S,3S)-3-fluoro-2-hydroxycyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxylic acid Chemical compound F[C@@H]1[C@H]([C@@H](CC1)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C)O CDVSPTPCZCIMOT-MISXGVKJSA-N 0.000 description 3
- MERINUYXHDUYPJ-DGCLKSJQSA-N 4-[[(3R,4R)-4-hydroxypyrrolidin-3-yl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carbaldehyde Chemical compound O[C@H]1[C@@H](CNC1)NC1=C2C(=NC=N1)N(N=C2C=O)COCC[Si](C)(C)C MERINUYXHDUYPJ-DGCLKSJQSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BCCSRVMJUHXTDQ-KNKQGSTJSA-N BrC1=C(CN(C(=O)C2=NN(C3=NC=NC(=C32)N[C@H]2[C@@H]([C@@H](CC2)O)O)COCC[Si](C)(C)C)C)C=C(C=C1)Cl Chemical compound BrC1=C(CN(C(=O)C2=NN(C3=NC=NC(=C32)N[C@H]2[C@@H]([C@@H](CC2)O)O)COCC[Si](C)(C)C)C)C=C(C=C1)Cl BCCSRVMJUHXTDQ-KNKQGSTJSA-N 0.000 description 3
- LIXLKDPJQBKEEG-VXGBXAGGSA-N BrC1=NN(C2=NC=NC(=C21)N[C@H]1[C@@H](CCC1)O)COCC[Si](C)(C)C Chemical compound BrC1=NN(C2=NC=NC(=C21)N[C@H]1[C@@H](CCC1)O)COCC[Si](C)(C)C LIXLKDPJQBKEEG-VXGBXAGGSA-N 0.000 description 3
- VTXLCMRJSYHLCF-VIZSFHNOSA-N ClC=1C=CC(=C(CN(C(=O)C2=NN(C3=NC=NC(=C32)N[C@H]2[C@@H]([C@@H](CC2)O)O)COCC[Si](C)(C)C)C)C=1)C#N Chemical compound ClC=1C=CC(=C(CN(C(=O)C2=NN(C3=NC=NC(=C32)N[C@H]2[C@@H]([C@@H](CC2)O)O)COCC[Si](C)(C)C)C)C=1)C#N VTXLCMRJSYHLCF-VIZSFHNOSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- KBHSTICQVVDMQS-SNVBAGLBSA-N N-[(1R)-1-(2-chloro-5-fluoropyridin-3-yl)but-3-enyl]acetamide Chemical compound ClC1=NC=C(C=C1[C@@H](CC=C)NC(C)=O)F KBHSTICQVVDMQS-SNVBAGLBSA-N 0.000 description 3
- CUQAVBKLXGWTNE-MISYRCLQSA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1R,2R,4R)-2-hydroxy-4-methylsulfonylcyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound FC1=C(CNC(=O)C2=NN(C3=NC=NC(=C32)N[C@H]2[C@@H](C[C@@H](C2)S(=O)(=O)C)O)COCC[Si](C)(C)C)C=C(C=C1)F CUQAVBKLXGWTNE-MISYRCLQSA-N 0.000 description 3
- VTEGSIDIYBUPBF-WAOWUJCRSA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1R,2S,3S)-3-fluoro-2-hydroxycyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound C[Si](C)(C)CCOCN1N=C(C(=O)NCC2=C(F)C=CC(F)=C2)C2=C1N=CN=C2N[C@@H]1CC[C@H](F)[C@H]1O VTEGSIDIYBUPBF-WAOWUJCRSA-N 0.000 description 3
- PGTMGJIVVGWLCS-VXGBXAGGSA-N O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C Chemical compound O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C PGTMGJIVVGWLCS-VXGBXAGGSA-N 0.000 description 3
- PDBATZYSEGGECF-CHWSQXEVSA-N O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)N(N=C2C(=O)OC)COCC[Si](C)(C)C Chemical compound O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)N(N=C2C(=O)OC)COCC[Si](C)(C)C PDBATZYSEGGECF-CHWSQXEVSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- JMRSNMXWYFUSHO-UTLUCORTSA-N [(1S,2S,4R)-4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentyl] acetate Chemical compound C(C)(=O)O[C@@H]1[C@H](C[C@H](C1)O)NC(=O)OC(C)(C)C JMRSNMXWYFUSHO-UTLUCORTSA-N 0.000 description 3
- MVHLSTIRVKLGMB-GUBZILKMSA-N [(1S,2S,4S)-4-fluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentyl] acetate Chemical compound CC(=O)O[C@H]1C[C@@H](F)C[C@@H]1NC(=O)OC(C)(C)C MVHLSTIRVKLGMB-GUBZILKMSA-N 0.000 description 3
- DGLRTNGMJQIUPG-NJDAHSKKSA-N [(1r,2r,3r)-3-(dibenzylamino)-2-hydroxycyclopentyl] acetate Chemical compound O[C@H]1[C@H](OC(=O)C)CC[C@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 DGLRTNGMJQIUPG-NJDAHSKKSA-N 0.000 description 3
- UUXOKMQFVLIIAH-NSISKUIASA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@H]1[C@@H](C[C@H](C1)C(F)F)N Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)O[C@H]1[C@@H](C[C@H](C1)C(F)F)N UUXOKMQFVLIIAH-NSISKUIASA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 229960005061 crizotinib Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- PSBABBDEUFNFKJ-UHFFFAOYSA-N cyclopent-2-en-1-ol Chemical compound OC1CCC=C1 PSBABBDEUFNFKJ-UHFFFAOYSA-N 0.000 description 3
- ZLSJNMIPGGUJDC-UHFFFAOYSA-N cyclopent-3-en-1-yloxymethylbenzene Chemical compound C=1C=CC=CC=1COC1CC=CC1 ZLSJNMIPGGUJDC-UHFFFAOYSA-N 0.000 description 3
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 3
- YFPCLQKFNXUAAK-UHFFFAOYSA-N cyclopentyl acetate Chemical compound CC(=O)OC1CCCC1 YFPCLQKFNXUAAK-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- QCIYAEYRVFUFAP-UHFFFAOYSA-N hexane-2,3-diol Chemical compound CCCC(O)C(C)O QCIYAEYRVFUFAP-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- XDQSHKMDEPFBPJ-UEHLDXLESA-N methyl (1R,3R,4R)-3-[[3-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine-1-carbonyl]-2H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]-4-hydroxycyclopentane-1-carboxylate Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@H](C1)F)C(=O)C1=NNC2=NC=NC(=C21)N[C@@H]1C[C@H](C[C@H]1O)C(=O)OC XDQSHKMDEPFBPJ-UEHLDXLESA-N 0.000 description 3
- PAZJIWSNBFMHJH-MGPQQGTHSA-N methyl 4-[[(1R,2R,4R)-2-hydroxy-4-methylsulfonylcyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxylate Chemical compound O[C@H]1[C@@H](C[C@H](C1)S(=O)(=O)C)NC1=C2C(=NC=N1)N(N=C2C(=O)OC)COCC[Si](C)(C)C PAZJIWSNBFMHJH-MGPQQGTHSA-N 0.000 description 3
- UROCOLNPYOTSSX-YWPYICTPSA-N methyl 4-[[(1R,2S,3S)-3-fluoro-2-hydroxycyclopentyl]amino]-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-d]pyrimidine-3-carboxylate Chemical compound F[C@@H]1[C@H]([C@@H](CC1)NC1=C2C(=NC=N1)N(N=C2C(=O)OC)COCC[Si](C)(C)C)O UROCOLNPYOTSSX-YWPYICTPSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- CSMODDAVIVZUFY-LLVKDONJSA-N tert-butyl (2R)-2-(2-chloro-5-fluoropyridin-3-yl)-4-oxopyrrolidine-1-carboxylate Chemical compound ClC1=NC=C(C=C1[C@@H]1N(CC(C1)=O)C(=O)OC(C)(C)C)F CSMODDAVIVZUFY-LLVKDONJSA-N 0.000 description 3
- IMBMHLRNVAIPRG-GFCCVEGCSA-N tert-butyl (2R)-2-(5-fluoropyridin-3-yl)-4-oxopyrrolidine-1-carboxylate Chemical compound FC=1C=C(C=NC=1)[C@@H]1N(CC(C1)=O)C(=O)OC(C)(C)C IMBMHLRNVAIPRG-GFCCVEGCSA-N 0.000 description 3
- AXBIXVFQBHBANX-ZWNOBZJWSA-N tert-butyl (2R,4R)-2-(2,5-difluorophenyl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@@H](C1)O)C(=O)OC(C)(C)C AXBIXVFQBHBANX-ZWNOBZJWSA-N 0.000 description 3
- KAYCKDOHSXLUGH-MWLCHTKSSA-N tert-butyl (2R,4R)-2-(2-chloro-5-fluoropyridin-3-yl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound ClC1=NC=C(C=C1[C@@H]1N(C[C@@H](C1)O)C(=O)OC(C)(C)C)F KAYCKDOHSXLUGH-MWLCHTKSSA-N 0.000 description 3
- RYYFJUHFGMNLBX-VXGBXAGGSA-N tert-butyl (2R,4R)-2-(5-fluoropyridin-3-yl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound FC=1C=C(C=NC=1)[C@@H]1N(C[C@@H](C1)O)C(=O)OC(C)(C)C RYYFJUHFGMNLBX-VXGBXAGGSA-N 0.000 description 3
- NVDMQLHGSHTBDF-GXSJLCMTSA-N tert-butyl (2R,4S)-2-(2-chloro-5-fluoropyridin-3-yl)-4-fluoropyrrolidine-1-carboxylate Chemical compound ClC1=NC=C(C=C1[C@@H]1N(C[C@H](C1)F)C(=O)OC(C)(C)C)F NVDMQLHGSHTBDF-GXSJLCMTSA-N 0.000 description 3
- ULOOSVXEXPTHKY-QMTHXVAHSA-N tert-butyl (2R,4S)-4-cyano-2-(2,5-difluorophenyl)pyrrolidine-1-carboxylate Chemical compound C(#N)[C@H]1C[C@@H](N(C1)C(=O)OC(C)(C)C)C1=C(C=CC(=C1)F)F ULOOSVXEXPTHKY-QMTHXVAHSA-N 0.000 description 3
- DOJZBQXJHVDEQF-NWDGAFQWSA-N tert-butyl (2R,4S)-4-fluoro-2-(5-fluoropyridin-3-yl)pyrrolidine-1-carboxylate Chemical compound F[C@H]1C[C@@H](N(C1)C(=O)OC(C)(C)C)C=1C=NC=C(C=1)F DOJZBQXJHVDEQF-NWDGAFQWSA-N 0.000 description 3
- RYYFJUHFGMNLBX-JHJMLUEUSA-N tert-butyl (4R)-2-(5-fluoropyridin-3-yl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound FC=1C=C(C=NC=1)C1N(C[C@@H](C1)O)C(=O)OC(C)(C)C RYYFJUHFGMNLBX-JHJMLUEUSA-N 0.000 description 3
- BZVXSFDGVDJRIT-ZIAGYGMSSA-N tert-butyl n-[(1r,2r)-2-[tert-butyl(dimethyl)silyl]oxy-4-oxocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC(=O)C[C@H]1O[Si](C)(C)C(C)(C)C BZVXSFDGVDJRIT-ZIAGYGMSSA-N 0.000 description 3
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MAQPKLNGHGQJGE-YMVPXFTJSA-N (1R,2R,4S,5S,6S)-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonan-5-ol Chemical compound O[C@@H]1[C@@H]2OC(C)(C)O[C@@H]2[C@@H]2C[C@@H]21 MAQPKLNGHGQJGE-YMVPXFTJSA-N 0.000 description 2
- KGKOUXFBWHTEOL-ZDQHTEEMSA-N (1r,2s,3r)-3-aminocyclopentane-1,2-diol;hydrochloride Chemical compound Cl.N[C@@H]1CC[C@@H](O)[C@H]1O KGKOUXFBWHTEOL-ZDQHTEEMSA-N 0.000 description 2
- GDFBHCMFIUBEQT-UHFFFAOYSA-N (2,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1F GDFBHCMFIUBEQT-UHFFFAOYSA-N 0.000 description 2
- TWUQEYRTGHLALM-QYNIQEEDSA-N (3as,4r,6ar)-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-amine Chemical compound C1C[C@@H](N)[C@@H]2OC(C)(C)O[C@@H]21 TWUQEYRTGHLALM-QYNIQEEDSA-N 0.000 description 2
- PSOOETMCZCWPBV-XVMARJQXSA-N (3as,4s,6ar)-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-ol Chemical compound C1C[C@H](O)[C@@H]2OC(C)(C)O[C@@H]21 PSOOETMCZCWPBV-XVMARJQXSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IMQFWCDQEAIYJV-UHFFFAOYSA-N 2-chloro-5-fluoropyridine-3-carbaldehyde Chemical compound FC1=CN=C(Cl)C(C=O)=C1 IMQFWCDQEAIYJV-UHFFFAOYSA-N 0.000 description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
- MDFHFCAMBZNSLV-UHFFFAOYSA-N 3-bromo-4-chloro-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=NC=NC2=NNC(Br)=C12 MDFHFCAMBZNSLV-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- YKKYTXARWZGPEI-VHSXEESVSA-N 3-fluoro-5-[(2R,4S)-4-fluoropyrrolidin-2-yl]benzamide Chemical compound FC=1C=C(C(=O)N)C=C(C=1)[C@@H]1NC[C@H](C1)F YKKYTXARWZGPEI-VHSXEESVSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- CSUABHOMDQBGFZ-RSJOWCBRSA-N 329910-40-9 Chemical compound O=C1N[C@H]2[C@@H]3O[C@@H]3[C@@H]1C2 CSUABHOMDQBGFZ-RSJOWCBRSA-N 0.000 description 2
- IUEGEICUJXNFHM-HTRCEHHLSA-N 4-[[(1R,2R)-2-hydroxycyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carbaldehyde Chemical compound O[C@H]1[C@@H](CCC1)NC1=C2C(=NC=N1)NN=C2C=O IUEGEICUJXNFHM-HTRCEHHLSA-N 0.000 description 2
- BDJVWSZMWRFXSU-NQMVMOMDSA-N 4-[[(1R,2R,4R)-2-hydroxy-4-(2-hydroxypropan-2-yl)cyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carbaldehyde Chemical compound O[C@H]1[C@@H](C[C@H](C1)C(C)(C)O)NC1=C2C(=NC=N1)NN=C2C=O BDJVWSZMWRFXSU-NQMVMOMDSA-N 0.000 description 2
- FFGVIYUANJAFJS-UHFFFAOYSA-N 4-phenylmethoxycyclohexan-1-one Chemical compound C1CC(=O)CCC1OCC1=CC=CC=C1 FFGVIYUANJAFJS-UHFFFAOYSA-N 0.000 description 2
- MPPRFQSUSJLXAQ-IONNQARKSA-N 5-fluoro-3-[(2R,4S)-4-fluoropyrrolidin-2-yl]-2-methoxypyridine Chemical compound FC=1C=C(C(=NC=1)OC)[C@@H]1NC[C@H](C1)F MPPRFQSUSJLXAQ-IONNQARKSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MOGDFRWOENIEPK-MRVWCRGKSA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1R,2R,4R)-2-hydroxy-4-methylsulfonylcyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound FC1=C(CNC(=O)C2=NNC3=NC=NC(=C32)N[C@H]2[C@@H](C[C@@H](C2)S(=O)(=O)C)O)C=C(C=C1)F MOGDFRWOENIEPK-MRVWCRGKSA-N 0.000 description 2
- CMPKYIOCUOXKJG-YWPYICTPSA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1R,2S,3S)-3-fluoro-2-hydroxycyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound FC1=C(CNC(=O)C2=NNC3=NC=NC(=C32)N[C@H]2[C@@H]([C@H](CC2)F)O)C=C(C=C1)F CMPKYIOCUOXKJG-YWPYICTPSA-N 0.000 description 2
- CMPKYIOCUOXKJG-XUJVJEKNSA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1S,2R,3R)-3-fluoro-2-hydroxycyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound FC1=C(CNC(=O)C2=NNC3=NC=NC(=C32)N[C@@H]2[C@H]([C@@H](CC2)F)O)C=C(C=C1)F CMPKYIOCUOXKJG-XUJVJEKNSA-N 0.000 description 2
- IKSGXZWOGVGLOD-CPUCHLNUSA-N N-[(5-chloro-2-cyanophenyl)methyl]-4-[[(1R,2S,3R)-2,3-dihydroxycyclopentyl]amino]-N-methyl-2H-pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound ClC=1C=CC(=C(CN(C(=O)C2=NNC3=NC=NC(=C32)N[C@H]2[C@@H]([C@@H](CC2)O)O)C)C=1)C#N IKSGXZWOGVGLOD-CPUCHLNUSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 2
- WRRBWAZRKBXRPO-XDDVRUDJSA-N [4-[[(1R,2R,4R)-4-(difluoromethyl)-2-hydroxycyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidin-3-yl]-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]methanone Chemical compound FC([C@H]1C[C@H]([C@@H](C1)NC1=C2C(=NC=N1)NN=C2C(=O)N1[C@H](C[C@@H](C1)F)C1=C(C=CC(=C1)F)F)O)F WRRBWAZRKBXRPO-XDDVRUDJSA-N 0.000 description 2
- MNZADOWXRIEHNS-UHFFFAOYSA-M [Br-].FC1=CC=C(F)C([Mg+])=C1 Chemical compound [Br-].FC1=CC=C(F)C([Mg+])=C1 MNZADOWXRIEHNS-UHFFFAOYSA-M 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 2
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 2
- 208000030173 low grade glioma Diseases 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- MDEBHDWZTOGBQT-RKDXNWHRSA-N methyl (3r,4r)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentene-1-carboxylate Chemical compound COC(=O)C1=C[C@@H](O)[C@H](NC(=O)OC(C)(C)C)C1 MDEBHDWZTOGBQT-RKDXNWHRSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- KAYCKDOHSXLUGH-HCCKASOXSA-N tert-butyl (2R)-2-(2-chloro-5-fluoropyridin-3-yl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound ClC1=NC=C(C=C1[C@@H]1N(CC(C1)O)C(=O)OC(C)(C)C)F KAYCKDOHSXLUGH-HCCKASOXSA-N 0.000 description 2
- ZJIYUHDEKBREJP-MGPQQGTHSA-N tert-butyl n-[(1r,2r,4r)-2-[tert-butyl(dimethyl)silyl]oxy-4-hydroxycyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](O)C[C@H]1O[Si](C)(C)C(C)(C)C ZJIYUHDEKBREJP-MGPQQGTHSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- IOGISYQVOGVIEU-UHFFFAOYSA-N (-4-Hydroxy-2-pyrrolidone Natural products OC1CNC(=O)C1 IOGISYQVOGVIEU-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- ZFSXKSSWYSZPGQ-TYSVMGFPSA-N (1r,2r)-2-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.N[C@@H]1CCC[C@H]1O ZFSXKSSWYSZPGQ-TYSVMGFPSA-N 0.000 description 1
- JBSOEJULKZXSPK-WDCZJNDASA-N (1r,2s,3r)-3-aminocyclopentane-1,2-diol Chemical compound N[C@@H]1CC[C@@H](O)[C@H]1O JBSOEJULKZXSPK-WDCZJNDASA-N 0.000 description 1
- DDUFYKNOXPZZIW-UHNVWZDZSA-N (1s,4r)-3-azabicyclo[2.2.1]hept-5-en-2-one Chemical compound C1[C@@H]2C(=O)N[C@H]1C=C2 DDUFYKNOXPZZIW-UHNVWZDZSA-N 0.000 description 1
- VYXHVRARDIDEHS-QGTKBVGQSA-N (1z,5z)-cycloocta-1,5-diene Chemical compound C\1C\C=C/CC\C=C/1 VYXHVRARDIDEHS-QGTKBVGQSA-N 0.000 description 1
- NCXSNNVYILYEBC-SNVBAGLBSA-N (2r)-2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=CC=C(F)C([C@@H]2NCCC2)=C1 NCXSNNVYILYEBC-SNVBAGLBSA-N 0.000 description 1
- AYIYPHDKKVWZKI-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;piperazine Chemical compound C1CNCCN1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO AYIYPHDKKVWZKI-LJTMIZJLSA-N 0.000 description 1
- SMQYQMQTCFRHEJ-OIBJUYFYSA-N (2r,4s)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine Chemical compound C1[C@H](F)CN[C@H]1C1=CC(F)=CC=C1F SMQYQMQTCFRHEJ-OIBJUYFYSA-N 0.000 description 1
- IRCDUOCGSIGEAI-XUXIUFHCSA-N (2s,5s)-1-[2-[(2s,5s)-2,5-dimethylphospholan-1-yl]ethyl]-2,5-dimethylphospholane Chemical compound C[C@H]1CC[C@H](C)P1CCP1[C@@H](C)CC[C@@H]1C IRCDUOCGSIGEAI-XUXIUFHCSA-N 0.000 description 1
- AXPYGRDXRLICKY-JRTVQGFMSA-N (3ar,4s,6r,6as)-6-amino-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-ol Chemical compound N[C@@H]1C[C@H](O)[C@H]2OC(C)(C)O[C@H]21 AXPYGRDXRLICKY-JRTVQGFMSA-N 0.000 description 1
- IOGISYQVOGVIEU-GSVOUGTGSA-N (4r)-4-hydroxypyrrolidin-2-one Chemical compound O[C@H]1CNC(=O)C1 IOGISYQVOGVIEU-GSVOUGTGSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LUCJQCWSQUBWDD-HQYNXSMWSA-N (NE,R)-N-[(2-chloro-5-fluoropyridin-3-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound ClC1=NC=C(C=C1\C=N\[S@](=O)C(C)(C)C)F LUCJQCWSQUBWDD-HQYNXSMWSA-N 0.000 description 1
- LUCJQCWSQUBWDD-HSLRFEFHSA-N (NZ,S)-N-[(2-chloro-5-fluoropyridin-3-yl)methylidene]-2-methylpropane-2-sulfinamide Chemical compound ClC1=NC=C(C=C1\C=N/[S@@](=O)C(C)(C)C)F LUCJQCWSQUBWDD-HSLRFEFHSA-N 0.000 description 1
- KPZPSEIHRIDPKH-UHFFFAOYSA-N 1,2,3,4-tetrahydro-2,6-naphthyridine Chemical compound N1=CC=C2CNCCC2=C1 KPZPSEIHRIDPKH-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- NGOTYFZFWPHNSU-UHFFFAOYSA-N 1,3-dioxol-4-amine Chemical compound NC1=COCO1 NGOTYFZFWPHNSU-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- RTIPTGMVQIIMKL-UHFFFAOYSA-N 1-bromo-4-chloro-2-methylbenzene Chemical compound CC1=CC(Cl)=CC=C1Br RTIPTGMVQIIMKL-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical group C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- QRTAWJHVRQCBIP-UHFFFAOYSA-N 2-amino-5-fluorocyclopentan-1-ol Chemical compound NC1C(C(CC1)F)O QRTAWJHVRQCBIP-UHFFFAOYSA-N 0.000 description 1
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- IBUQIRGOEBUDFB-UHFFFAOYSA-N 3,4-dihydro-1h-pyrano[4,3-c]pyridine Chemical compound N1=CC=C2COCCC2=C1 IBUQIRGOEBUDFB-UHFFFAOYSA-N 0.000 description 1
- HNNNBQRRIHKFLI-UHFFFAOYSA-N 3-bromo-5-fluoropyridine Chemical compound FC1=CN=CC(Br)=C1 HNNNBQRRIHKFLI-UHFFFAOYSA-N 0.000 description 1
- COKHMUBYEFXMPJ-WDEREUQCSA-N 3-fluoro-5-[(2r,4s)-4-fluoropyrrolidin-2-yl]benzonitrile Chemical compound C1[C@H](F)CN[C@H]1C1=CC(F)=CC(C#N)=C1 COKHMUBYEFXMPJ-WDEREUQCSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- GVCLNACSYKYUHP-UHFFFAOYSA-N 4-amino-7-(2-hydroxyethoxymethyl)pyrrolo[2,3-d]pyrimidine-5-carbothioamide Chemical compound C1=NC(N)=C2C(C(=S)N)=CN(COCCO)C2=N1 GVCLNACSYKYUHP-UHFFFAOYSA-N 0.000 description 1
- WSTUJEXAPHIEIM-UHFFFAOYSA-N 4-fluoro-n-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide Chemical compound C1CC(C(=O)NC(C)C)CCC1N(C=1C(=CC=C(CN2CCC(CC2)C(C)(C)O)C=1)N\1)C/1=N/C(=O)C1=CC=C(F)C=C1 WSTUJEXAPHIEIM-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- YAGPZRLCMRMSFP-UHFFFAOYSA-N 5-fluoro-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(F)C=C1C=O YAGPZRLCMRMSFP-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- TZTBFEPKIZUYCZ-UHFFFAOYSA-N 6H-cyclopenta[d][1,3]dioxol-5-ol Chemical compound O1COC2=C1C=C(C2)O TZTBFEPKIZUYCZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000937413 Axia Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QEOSRTPSNGYFLV-WMLDXEAASA-N FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@H](C1)F)C(=O)C1=NN(C=2N=CNC(C=21)=O)COCC[Si](C)(C)C Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@H](C1)F)C(=O)C1=NN(C=2N=CNC(C=21)=O)COCC[Si](C)(C)C QEOSRTPSNGYFLV-WMLDXEAASA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- MOGDFRWOENIEPK-UBHSHLNASA-N N-[(2,5-difluorophenyl)methyl]-4-[[(1S,2S,4S)-2-hydroxy-4-methylsulfonylcyclopentyl]amino]-2H-pyrazolo[3,4-d]pyrimidine-3-carboxamide Chemical compound FC1=C(CNC(=O)C2=NNC3=NC=NC(=C32)N[C@@H]2[C@H](C[C@H](C2)S(=O)(=O)C)O)C=C(C=C1)F MOGDFRWOENIEPK-UBHSHLNASA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910017833 NH2NH2.H2O Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- KDQLGFZYYZEKJQ-UHFFFAOYSA-N O=C1C2=C(N=CN1)N(N=C2C(=O)O)COCC[Si](C)(C)C Chemical compound O=C1C2=C(N=CN1)N(N=C2C(=O)O)COCC[Si](C)(C)C KDQLGFZYYZEKJQ-UHFFFAOYSA-N 0.000 description 1
- SQZBZOJKIWLRMJ-GYSYKLTISA-N O[C@H]1[C@@H](CC[C@H]1O)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C Chemical compound O[C@H]1[C@@H](CC[C@H]1O)NC1=C2C(=NC=N1)N(N=C2C(=O)O)COCC[Si](C)(C)C SQZBZOJKIWLRMJ-GYSYKLTISA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- JMRSNMXWYFUSHO-IVZWLZJFSA-N [(1R,2R,4S)-4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentyl] acetate Chemical compound C(C)(=O)O[C@H]1[C@@H](C[C@@H](C1)O)NC(=O)OC(C)(C)C JMRSNMXWYFUSHO-IVZWLZJFSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- OWKCFBYWQGPLSJ-DTWKUNHWSA-N [(3r,4s)-4-acetyloxy-3,4-dihydro-2h-pyran-3-yl] acetate Chemical compound CC(=O)O[C@@H]1COC=C[C@@H]1OC(C)=O OWKCFBYWQGPLSJ-DTWKUNHWSA-N 0.000 description 1
- RBBLJBDABBNVSF-UEHLDXLESA-N [4-[[(1R,2R,4R)-4-(difluoromethyl)-2-hydroxycyclopentyl]amino]-1-(hydroxymethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]methanone Chemical compound FC([C@H]1C[C@H]([C@@H](C1)NC1=C2C(=NC=N1)N(N=C2C(=O)N1[C@H](C[C@@H](C1)F)C1=C(C=CC(=C1)F)F)CO)O)F RBBLJBDABBNVSF-UEHLDXLESA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000024063 childhood astrocytic tumor Diseases 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940034568 cometriq Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- CKSVPIZNXAIFIN-OSMVPFSASA-N ctk7g2407 Chemical compound O=C1N(C(=O)OC(C)(C)C)[C@H]2[C@@H]3O[C@@H]3[C@@H]1C2 CKSVPIZNXAIFIN-OSMVPFSASA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- WEIMJSIRDZDHAH-UHFFFAOYSA-N cyclopent-3-en-1-ol Chemical compound OC1CC=CC1 WEIMJSIRDZDHAH-UHFFFAOYSA-N 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940049235 iclusig Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000011628 juvenile astrocytoma Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- WEYYRKZVUXNNES-OMCPHZPLSA-N methyl (1R,3R,4R)-3-[[3-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine-1-carbonyl]-1-(hydroxymethyl)pyrazolo[3,4-d]pyrimidin-4-yl]amino]-4-hydroxycyclopentane-1-carboxylate Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C[C@H](C1)F)C(=O)C1=NN(C2=NC=NC(=C21)N[C@@H]1C[C@H](C[C@H]1O)C(=O)OC)CO WEYYRKZVUXNNES-OMCPHZPLSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- KDDNIXNWBDKJCN-UHFFFAOYSA-N n,n-dibenzylcyclopent-2-en-1-amine Chemical compound C=1C=CC=CC=1CN(C1C=CCC1)CC1=CC=CC=C1 KDDNIXNWBDKJCN-UHFFFAOYSA-N 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical group 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 201000002526 pancreas sarcoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- DOJZBQXJHVDEQF-RYUDHWBXSA-N tert-butyl (2S,4S)-4-fluoro-2-(5-fluoropyridin-3-yl)pyrrolidine-1-carboxylate Chemical compound F[C@H]1C[C@H](N(C1)C(=O)OC(C)(C)C)C=1C=NC=C(C=1)F DOJZBQXJHVDEQF-RYUDHWBXSA-N 0.000 description 1
- MOZOQDNRVPHFOO-RNFRBKRXSA-N tert-butyl (3r,4r)-3-amino-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@@H](N)[C@H](O)C1 MOZOQDNRVPHFOO-RNFRBKRXSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940049068 xalkori Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210264P | 2015-08-26 | 2015-08-26 | |
| US62/210,264 | 2015-08-26 | ||
| PCT/US2016/048698 WO2017035354A1 (en) | 2015-08-26 | 2016-08-25 | Compounds and compositions useful for treating disorders related to ntrk |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018110379A RU2018110379A (ru) | 2019-09-27 |
| RU2018110379A3 RU2018110379A3 (https=) | 2019-12-26 |
| RU2744974C2 true RU2744974C2 (ru) | 2021-03-17 |
Family
ID=56896780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018110379A RU2744974C2 (ru) | 2015-08-26 | 2016-08-25 | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10017512B2 (https=) |
| EP (1) | EP3341374A1 (https=) |
| JP (1) | JP6877407B2 (https=) |
| KR (1) | KR20180043810A (https=) |
| CN (1) | CN108137607B (https=) |
| AR (1) | AR105836A1 (https=) |
| AU (1) | AU2016311426B2 (https=) |
| BR (1) | BR112018003588A2 (https=) |
| CA (1) | CA2995997A1 (https=) |
| HK (1) | HK1255330A1 (https=) |
| IL (1) | IL257702A (https=) |
| MX (1) | MX2018002407A (https=) |
| PH (1) | PH12018500397A1 (https=) |
| RU (1) | RU2744974C2 (https=) |
| TW (1) | TW201713665A (https=) |
| WO (1) | WO2017035354A1 (https=) |
| ZA (1) | ZA201801881B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| DK3674307T3 (da) | 2017-08-23 | 2023-09-11 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf |
| WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
| WO2019152982A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic compounds as ep4 antagonists |
| BR112020019399A2 (pt) * | 2018-03-28 | 2021-01-05 | Fochon Pharmaceuticals, Ltd. | Compostos macrocíclicos como inibidores de trk quinases |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| MX2021010173A (es) * | 2019-02-27 | 2021-12-10 | Ferro Therapeutics Inc | Compuestos con actividad inductora de ferroptosis y métodos de uso. |
| WO2020210669A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| EP4065585B1 (en) * | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| RU2379308C2 (ru) * | 2004-04-02 | 2010-01-20 | Оси Фармасьютикалз, Инк. | 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ |
| WO2011139273A1 (en) * | 2010-05-05 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| WO2014118226A1 (en) * | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251911B1 (en) * | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| PT1537116E (pt) | 2002-09-04 | 2010-09-03 | Schering Corp | Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| CA2882759C (en) * | 2012-08-31 | 2018-11-20 | The Regents Of The University Of Colorado | Detection of the ntrk1-mprip gene fusion for cancer diagnosis |
| KR20150072412A (ko) | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| CN107531666A (zh) | 2015-02-20 | 2018-01-02 | 里格尔药品股份有限公司 | Gdf‑8抑制剂 |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 HK HK18114466.6A patent/HK1255330A1/zh unknown
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en not_active Ceased
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja not_active Expired - Fee Related
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko not_active Withdrawn
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2379308C2 (ru) * | 2004-04-02 | 2010-01-20 | Оси Фармасьютикалз, Инк. | 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2011139273A1 (en) * | 2010-05-05 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| WO2014118226A1 (en) * | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
Non-Patent Citations (1)
| Title |
|---|
| P.Traxler et al. Use of A Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines. J.Med.Chem., 1997, 40(22), 3601-3616. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180043810A (ko) | 2018-04-30 |
| PH12018500397A1 (en) | 2018-08-29 |
| AU2016311426A1 (en) | 2018-04-05 |
| US10017512B2 (en) | 2018-07-10 |
| ZA201801881B (en) | 2019-05-29 |
| WO2017035354A1 (en) | 2017-03-02 |
| CA2995997A1 (en) | 2017-03-02 |
| US20170066773A1 (en) | 2017-03-09 |
| AU2016311426B2 (en) | 2021-05-20 |
| RU2018110379A3 (https=) | 2019-12-26 |
| US20190169194A1 (en) | 2019-06-06 |
| AR105836A1 (es) | 2017-11-15 |
| JP6877407B2 (ja) | 2021-05-26 |
| TW201713665A (zh) | 2017-04-16 |
| CN108137607A (zh) | 2018-06-08 |
| MX2018002407A (es) | 2018-11-29 |
| HK1255330A1 (zh) | 2019-08-16 |
| EP3341374A1 (en) | 2018-07-04 |
| IL257702A (en) | 2018-04-30 |
| BR112018003588A2 (pt) | 2018-09-25 |
| US11046697B2 (en) | 2021-06-29 |
| RU2018110379A (ru) | 2019-09-27 |
| JP2018528200A (ja) | 2018-09-27 |
| CN108137607B (zh) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2744974C2 (ru) | Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk | |
| US12595265B2 (en) | Inhibitors of activin receptor-like kinase | |
| TWI733713B (zh) | 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物 | |
| JP6494624B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| KR102713058B1 (ko) | 히스톤 아세틸라제 p300 억제제 및 그 용도 | |
| CN114286822A (zh) | 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 | |
| JP2023522863A (ja) | Ｅｇｆｒ阻害剤としての三環式化合物 | |
| JP6718553B2 (ja) | 突然変異型ｉｄｈ抑制活性を有する化合物、その製造方法および使用 | |
| JP2025519624A (ja) | Ｈｐｋ１阻害剤およびその医薬における使用 | |
| HK40068189A (en) | Compound as small molecule inhibitor pd-1/pd-l1 and application thereof | |
| EA040675B1 (ru) | Ингибиторы активин-подобной рецепторной киназы | |
| HK40003732A (en) | Inhibitors of activin receptor-like kinase |